eli lilly retatrutide phase 3 trial Medscape | Retatrutide, Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Starting Phase 3b Clinical Trial

Here are the key populations where the comparison shifts

The platform integrates nutrition coaching, realistic physical activity goals, and emotional health support to help you manage stress and maintain long-term success

Speed and IP protection drive synthetic DNA procurement decisionsas synthesis fidelity has improved, quality is relatively standard across commercial synthetic DNA providers, removing a competitive lever that might favor higher-standard U.S., Japanese, or European producers

Assignment depends on etiology: idiopathic/cryptogenic SFN G60.3 (idiopathic progressive neuropathy) or G62.89 (other specified polyneuropathy)

Another study investigated the effect of GLP-1 RAs on IIH symptoms, such as monthly headache days and visual outcomes